



# ALGERIA

Number of new cases

**64 713**

Number of deaths

**35 778**

Number of prevalent cases (5-year)




**177 718**

## Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	22 912 687	22 437 454	45 350 141
<b>Incidence*</b>			
Number of new cancer cases	29 387	35 326	64 713
Age-standardized incidence rate	130.6	152.2	141.2
Risk of developing cancer before the age of 75 years (cum. risk %)	14.1	15.1	14.6
<b>Top 3 leading cancers (ranked by cases)**</b>	Lung Colorectum Prostate	Breast Colorectum Thyroid	Breast Colorectum Lung
<b>Mortality*</b>			
Number of cancer deaths	18 809	16 969	35 778
Age-standardized mortality rate	82.7	73.1	77.7
Risk of dying from cancer before the age of 75 years (cum. risk %)	8.7	7.8	8.2
<b>Top 3 leading cancers (ranked by deaths)**</b>	Lung Colorectum Bladder	Breast Colorectum Cervix uteri	Breast Lung Colorectum
<b>Prevalence*</b>			
5-year prevalent cases	72 408	105 310	177 718



## Top 5 most frequent cancers\*\*



Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Breast	14 601	1	22.6	6.3	4 893	1	13.7	2.2	47 259	210.6
Colorectum	7 747	2	12.0	2.0	4 380	3	12.2	1.0	22 192	48.9
Lung	5 040	3	7.8	1.4	4 599	2	12.9	1.3	6 725	14.8
Prostate	3 514	4	5.4	1.9	1 333	7	3.7	0.19	8 124	35.5
Bladder	3 240	5	5.0	0.90	1 818	5	5.1	0.43	9 863	21.8
Stomach	2 785	6	4.3	0.72	2 250	4	6.3	0.57	4 330	9.6
Thyroid	2 519	7	3.9	0.55	358	19	1.0	0.07	8 599	19.0
NHL	2 226	8	3.4	0.51	1 187	8	3.3	0.27	7 118	15.7
Brain CNS	2 038	9	3.1	0.44	1 575	6	4.4	0.38	7 675	16.9
Cervix uteri	1 799	10	2.8	0.94	1 013	11	2.8	0.57	5 442	24.3
Leukaemia	1 731	11	2.7	0.34	1 167	9	3.3	0.24	5 323	11.7
Nasopharynx	1 608	12	2.5	0.37	971	12	2.7	0.26	5 125	11.3
Gallbladder	1 193	13	1.8	0.32	785	14	2.2	0.19	1 733	3.8
Pancreas	1 168	14	1.8	0.30	1 136	10	3.2	0.30	1 193	2.6
Ovary	1 147	15	1.8	0.57	795	13	2.2	0.44	3 444	15.4
Hodgkin lymphoma	999	16	1.5	0.18	278	20	0.78	0.06	3 649	8.1
Larynx	961	17	1.5	0.28	627	17	1.8	0.17	2 970	6.6
Multiple myeloma	770	18	1.2	0.21	655	16	1.8	0.18	2 154	4.8
Liver	755	19	1.2	0.19	663	15	1.9	0.17	1 010	2.2
Kidney	729	20	1.1	0.18	371	18	1.0	0.09	2 263	5.0
Corpus uteri	593	21	0.92	0.33	124	23	0.35	0.07	2 097	9.4
Lip, oral cavity	343	22	0.53	0.09	146	22	0.41	0.04	997	2.2
Melanoma	306	23	0.47	0.07	113	24	0.32	0.02	1 018	2.2
Oesophagus	285	24	0.44	0.06	266	21	0.74	0.06	413	0.91
Testis	163	25	0.25	0.06	29	30	0.08	0.01	611	2.7
Salivary glands	152	26	0.24	0.03	59	26	0.17	0.01	481	1.1
Vulva	97	27	0.15	0.05	36	29	0.10	0.02	277	1.2
Oropharynx	90	28	0.14	0.02	53	27	0.15	0.01	228	0.50
Hypopharynx	77	29	0.12	0.02	41	28	0.12	0.01	135	0.30
Mesothelioma	69	30	0.11	0.02	65	25	0.18	0.02	96	0.21
Kaposi sarcoma	62	31	0.10	0.01	28	31	0.08	0.00	124	0.27
Vagina	49	32	0.08	0.02	24	32	0.07	0.01	123	0.55
<b>All cancers</b>	<b>64 713</b>	-	-	<b>14.6</b>	<b>35 778</b>	-	-	<b>8.2</b>	<b>177 718</b>	-
<b>All cancers excl. NMSC</b>	<b>63 306</b>	-	-	<b>14.3</b>	<b>35 347</b>	-	-	<b>8.2</b>	<b>173 172</b>	-

## Data source and methods

### Incidence

**Country-specific data source:** Setif cancer registry, Algiers cancer registry, Batna cancer registry, Tlemcen cancer registry  
**Method:** Weighted/simple average of the most recent sub-national rates applied to 2022 population

[Click here to see detailed data source and methods](#)



### Mortality

**Country-specific data source:** Survival estimates  
**Method:** Estimated from national incidence estimates by modelling, using mortality:incidence ratios derived from survival estimation

[Click here to see detailed data source and methods](#)

### Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)

\*\* NMSC included in other cancers

Age standardization using world population ([see link](#))

## References

### Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

### Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021 Feb 4. doi:10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. *Int J Cancer*. 2021 Apr 5. doi:10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

